Cerebral arterial air embolism after esophageal stenting for recurrence of gastroesophageal junction cancer: a case report.

Cerebral arterial air embolism Esophageal stenting Gastroesophageal junction adenocarcinoma Multiple cancer treatments

Journal

International cancer conference journal
ISSN: 2192-3183
Titre abrégé: Int Cancer Conf J
Pays: Singapore
ID NLM: 101734231

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 25 04 2024
accepted: 30 07 2024
pmc-release: 06 08 2025
medline: 14 10 2024
pubmed: 14 10 2024
entrez: 14 10 2024
Statut: epublish

Résumé

Cerebral arterial air embolism (CAE) is a rare complication after esophageal stenting, but it can be life-threatening. It is especially a concern for those with a history of previous gastrointestinal cancer therapies. We report a case of CAE after esophageal stenting in a patient with recurrent gastroesophageal junction cancer and a history of multiple cancer treatments. A 71 year-old man with a history of a proximal gastrectomy, resection of the lower esophagus, chemotherapy, and radiation presented to our hospital 2 weeks after stenting with epigastric and back pain. Mediastinitis was suspected and conservative treatment was begun. The patient suddenly developed altered mental status, left hemiplegia, and anisocoria after drinking water. A brain computed tomography (CT) revealed right-sided predominance of multifocal CAE. Chest and abdominal CT showed a hematoma in the gastric and duodenal wall and an intraluminal hematoma from the esophagus, around the stent, to the upper ileum. CAE was thought to be due to rupture of the recurrent tumor. Unfortunately, despite intensive care, the patient died about 5 h after the onset of neurological symptoms. It has been reported that prior treatments, such as chemotherapy and radiotherapy, increase the risk of life-threatening adverse events, including CAE after esophageal stenting. Clinicians should keep in mind the possibility of CAE after esophageal stenting in patients with a history of multiple cancer treatments.

Identifiants

pubmed: 39398936
doi: 10.1007/s13691-024-00710-5
pii: 710
pmc: PMC11464815
doi:

Types de publication

Journal Article

Langues

eng

Pagination

460-467

Informations de copyright

© The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Déclaration de conflit d'intérêts

Conflict of interestThe authors declare that they have no conflict of interest.

Auteurs

Susumu Saigusa (S)

Department of Surgery, IGA City General Hospital, 831 Shijuku-cho, Iga, Mie 518-0823 Japan.

Yuki Aono (Y)

Department of Gastroenterology and Hepatology, IGA City General Hospital, 831 Shijuku-cho, Iga, Mie 518-0823 Japan.

Hiroyuki Fujikawa (H)

Department of Surgery, IGA City General Hospital, 831 Shijuku-cho, Iga, Mie 518-0823 Japan.

Ryo Uratani (R)

Department of Gastrointestinal and Pediatric Surgery, Mie University Hospital, 2-174 Edobashi, Tsu, Mie 514-8507 Japan.

Shuyo Watanabe (S)

Department of Surgery, IGA City General Hospital, 831 Shijuku-cho, Iga, Mie 518-0823 Japan.

Hiroyuki Sakurai (H)

Department of Surgery, IGA City General Hospital, 831 Shijuku-cho, Iga, Mie 518-0823 Japan.

Masaki Ohi (M)

Department of Gastrointestinal and Pediatric Surgery, Mie University Hospital, 2-174 Edobashi, Tsu, Mie 514-8507 Japan.

Koji Tanaka (K)

Department of Surgery, IGA City General Hospital, 831 Shijuku-cho, Iga, Mie 518-0823 Japan.

Classifications MeSH